Roland Magnusson
- AstraZeneca (NASDAQ:AZN) has received FDA Breakthrough Therapy Designation for its drug Dato-DXd, also known as datopotamab deruxtecan, for the treatment of EGFR-mutated lung cancer.
- The drug received the designation for locally advanced or metastatic EGFR-mutated non-small cell lung cancer with
